What is the current valuation of the equine healthcare market in Germany?

The market valuation was $129.69 Million in 2024. Read More

What is the projected market size for the equine healthcare sector by 2035?

The projected valuation for 2035 is $269.88 Million. Read More

What is the expected CAGR for the equine healthcare market from 2025 to 2035?

The expected CAGR during the forecast period is 6.89%. Read More

Which companies are the key players in the German equine healthcare market?

Key players include Merck Animal Health, Zoetis, Boehringer Ingelheim, and Elanco Animal Health. Read More

What are the main product segments in the equine healthcare market?

Main product segments include Vaccines, Pharmaceuticals, and Diagnostics, with valuations ranging from $10.0 Million to $80.0 Million. Read More

What are the leading indications for equine healthcare products?

Leading indications include Musculoskeletal Disorders and Parasite Control, with valuations between $20.0 Million and $52.0 Million. Read More

How is the equine healthcare market distributed across different channels?

Distribution channels include Veterinary Hospitals & Clinics and E-commerce, with valuations from $19.69 Million to $150.0 Million. Read More

What activities drive the demand for equine healthcare products?

Demand is driven by Sports/Racing and Recreation activities, with valuations between $39.69 Million and $100.0 Million. Read More

What is the valuation range for pharmaceuticals in the equine healthcare market?

The valuation range for pharmaceuticals is between $40.0 Million and $80.0 Million. Read More

How does the equine healthcare market in Germany compare to other regions?

While specific comparisons are not provided, the growth trajectory suggests a robust market presence in Germany. Read More

Germany Equine Healthcare Market

ID: MRFR/HC/50662-HCR

200 Pages

Nidhi Mandole

Last Updated: February 06, 2026

Germany Equine Healthcare Market Research Report: Size, Share, Trend Analysis By Product (Vaccines, Pharmaceuticals, Medicinal Feed Additives, Diagnostics, Software & Services, Others), By Indication (Musculoskeletal Disorders, Parasite Control, Internal Medicine, Equine Herpes Virus, Equine Encephalomyelitis, Equine Influenza, West Nile Virus, Tetanus, Others), By Activity (Sports/Racing, Recreation, Others) and By Distribution Channel (Veterinary Hospitals & Clinics, E-commerce, Others) - Growth Outlook & Industry Forecast 2025 To 2035

Germany Equine Healthcare Market

Market Size

Forecast Period2025 - 2035

CAGR (2025 - 2035)6.89%

2024 Market Size$ 129.69 Million

2025 Market Size$ 138.62 Million

2035 Market Size$ 269.88 Million

Key Players

Merck Animal Health

Zoetis

Boehringer Ingelheim

Elanco Animal Health

Vetoquinol

Dechra Pharmaceuticals

Trends

Increased Focus on Preventive Care
Technological Advancements in Veterinary Medicine
Rise of Natural and Organic Products

Opportunities

Expansion of Equine Health Insurance Options
Rising Awareness of Equine Welfare Standards
Increased Investment in Equine Health Research

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Pharmaceutical, BY Product (USD Million)
  1. 4.1.1 Vaccines
  2. 4.1.2 Pharmaceuticals
  3. 4.1.3 Medicinal Feed Additives
  4. 4.1.4 Diagnostics
  5. 4.1.5 Software & Services
  6. 4.1.6 Others
2. 4.2 Pharmaceutical, BY Indication (USD Million)
  1. 4.2.1 Musculoskeletal Disorders
  2. 4.2.2 Parasite Control
  3. 4.2.3 Internal Medicine
  4. 4.2.4 Equine Herpes Virus
  5. 4.2.5 Equine Encephalomyelitis
  6. 4.2.6 Equine Influenza
  7. 4.2.7 West Nile Virus
  8. 4.2.8 Tetanus
  9. 4.2.9 Others
3. 4.3 Pharmaceutical, BY Activity (USD Million)
  1. 4.3.1 Sports/Racing
  2. 4.3.2 Recreation
  3. 4.3.3 Others
4. 4.4 Pharmaceutical, BY Distribution Channel (USD Million)
  1. 4.4.1 Veterinary Hospitals & Clinics
  2. 4.4.2 E-commerce
  3. 4.4.3 Others
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Pharmaceutical
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Pharmaceutical
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Merck Animal Health (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Zoetis (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Boehringer Ingelheim (DE)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Elanco Animal Health (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Vetoquinol (FR)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Dechra Pharmaceuticals (GB)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Cegelec (FR)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Heska Corporation (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Vetmedin (DE)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 GERMANY MARKET ANALYSIS BY PRODUCT
3. 6.3 GERMANY MARKET ANALYSIS BY INDICATION
4. 6.4 GERMANY MARKET ANALYSIS BY ACTIVITY
5. 6.5 GERMANY MARKET ANALYSIS BY DISTRIBUTION CHANNEL
6. 6.6 KEY BUYING CRITERIA OF PHARMACEUTICAL
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF PHARMACEUTICAL
9. 6.9 DRIVERS IMPACT ANALYSIS: PHARMACEUTICAL
10. 6.10 RESTRAINTS IMPACT ANALYSIS: PHARMACEUTICAL
11. 6.11 SUPPLY / VALUE CHAIN: PHARMACEUTICAL
12. 6.12 PHARMACEUTICAL, BY PRODUCT, 2024 (% SHARE)
13. 6.13 PHARMACEUTICAL, BY PRODUCT, 2024 TO 2035 (USD Million)
14. 6.14 PHARMACEUTICAL, BY INDICATION, 2024 (% SHARE)
15. 6.15 PHARMACEUTICAL, BY INDICATION, 2024 TO 2035 (USD Million)
16. 6.16 PHARMACEUTICAL, BY ACTIVITY, 2024 (% SHARE)
17. 6.17 PHARMACEUTICAL, BY ACTIVITY, 2024 TO 2035 (USD Million)
18. 6.18 PHARMACEUTICAL, BY DISTRIBUTION CHANNEL, 2024 (% SHARE)
19. 6.19 PHARMACEUTICAL, BY DISTRIBUTION CHANNEL, 2024 TO 2035 (USD Million)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 Germany MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY PRODUCT, 2025-2035 (USD Million)
  2. 7.2.2 BY INDICATION, 2025-2035 (USD Million)
  3. 7.2.3 BY ACTIVITY, 2025-2035 (USD Million)
  4. 7.2.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

Germany Pharmaceutical Market Segmentation

Pharmaceutical By Product (USD Million, 2025-2035)

Vaccines
Pharmaceuticals
Medicinal Feed Additives
Diagnostics
Software & Services
Others

Pharmaceutical By Indication (USD Million, 2025-2035)

Musculoskeletal Disorders
Parasite Control
Internal Medicine
Equine Herpes Virus
Equine Encephalomyelitis
Equine Influenza
West Nile Virus
Tetanus
Others

Pharmaceutical By Activity (USD Million, 2025-2035)

Sports/Racing
Recreation
Others

Pharmaceutical By Distribution Channel (USD Million, 2025-2035)

Veterinary Hospitals & Clinics
E-commerce
Others

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”